<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38700094</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1532-2092</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Jun</Month><Day>03</Day></PubDate></JournalIssue><Title>Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology</Title><ISOAbbreviation>Europace</ISOAbbreviation></Journal><ArticleTitle>Antiarrhythmic drugs in the era of atrial fibrillation ablation.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">euae122</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/europace/euae122</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boriani</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-9820-4815</Identifier><AffiliationInfo><Affiliation>Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, Italy University of Modena and Reggio Emilia, Policlinico di Modena, Via del Pozzo 71, 41121 Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mei</LastName><ForeName>Davide Antonio</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0009-0000-6345-3742</Identifier><AffiliationInfo><Affiliation>Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, Italy University of Modena and Reggio Emilia, Policlinico di Modena, Via del Pozzo 71, 41121 Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imberti</LastName><ForeName>Jacopo Francesco</ForeName><Initials>JF</Initials><Identifier Source="ORCID">0000-0003-3403-3364</Identifier><AffiliationInfo><Affiliation>Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, Italy University of Modena and Reggio Emilia, Policlinico di Modena, Via del Pozzo 71, 41121 Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Europace</MedlineTA><NlmUniqueID>100883649</NlmUniqueID><ISSNLinking>1099-5129</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000889">Anti-Arrhythmia Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Europace. 2024 Jun 3;26(6):euae121. doi: 10.1093/europace/euae121.</RefSource><PMID Version="1">38702961</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="Y">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000889" MajorTopicYN="Y">Anti-Arrhythmia Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017115" MajorTopicYN="Y">Catheter Ablation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ablation</Keyword><Keyword MajorTopicYN="N">Antiarrhythmic drugs</Keyword><Keyword MajorTopicYN="N">Atrial fibrillation</Keyword><Keyword MajorTopicYN="N">Heart failure</Keyword><Keyword MajorTopicYN="N">Stroke</Keyword></KeywordList><CoiStatement>Conflict of interest: G.B. reported speaker fees of small amount from Bayer, Boston, Boehringer, Daiichi-Sankyo, Janssen, Sanofi, outside the submitted work. The other authors reported no conflict.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>6</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>3</Day><Hour>12</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>3</Day><Hour>7</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>5</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38700094</ArticleId><ArticleId IdType="pmc">PMC11154134</ArticleId><ArticleId IdType="doi">10.1093/europace/euae122</ArticleId><ArticleId IdType="pii">7663763</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Imberti &#xa0;JF, Ding &#xa0;WY, Kotalczyk &#xa0;A, Zhang &#xa0;J, Boriani &#xa0;G, Lip &#xa0;G, et al. &#xa0;Catheter ablation as first-line treatment for paroxysmal atrial fibrillation: a systematic review and meta-analysis. Heart &#xa0;2021;107:1630&#x2013;6. doi:10.1136/heartjnl-2021-319496</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2021-319496</ArticleId><ArticleId IdType="pubmed">34261737</ArticleId></ArticleIdList></Reference><Reference><Citation>Boersma &#xa0;L, Andrade &#xa0;JG, Betts &#xa0;T, Duytschaever &#xa0;M, P&#xfc;rerfellner &#xa0;H, Santoro &#xa0;F, et al. &#xa0;Progress in atrial fibrillation ablation during 25 years of Europace journal. Europace &#xa0;2023;25:euad244. doi:10.1093/europace/euad244</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euad244</ArticleId><ArticleId IdType="pmc">PMC10451004</ArticleId><ArticleId IdType="pubmed">37622592</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyse &#xa0;DG, Waldo &#xa0;AL, DiMarco &#xa0;JP, Domanski &#xa0;MJ, Rosenberg &#xa0;Y, Schron &#xa0;EB, Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators, et al. &#xa0;A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med &#xa0;2002;347:1825&#x2013;33. doi:10.1056/NEJMoa021328</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa021328</ArticleId><ArticleId IdType="pubmed">12466506</ArticleId></ArticleIdList></Reference><Reference><Citation>Echt &#xa0;DS, Liebson &#xa0;PR, Mitchell &#xa0;LB, Peters &#xa0;RW, Obias-Manno &#xa0;D, Barker &#xa0;AH, et al. &#xa0;Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med &#xa0;1991;324:781&#x2013;8. doi:10.1056/NEJM199103213241201</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199103213241201</ArticleId><ArticleId IdType="pubmed">1900101</ArticleId></ArticleIdList></Reference><Reference><Citation>Hindricks &#xa0;G, Potpara &#xa0;T, Dagres &#xa0;N, Arbelo &#xa0;E, Bax &#xa0;JJ, Blomstr&#xf6;m-Lundqvist &#xa0;C, et al. &#xa0;2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J &#xa0;2021;42:373&#x2013;498. doi:10.1093/eurheartj/ehaa612</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa612</ArticleId><ArticleId IdType="pubmed">32860505</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchhof &#xa0;P, Camm &#xa0;AJ, Goette &#xa0;A, Brandes &#xa0;A, Eckardt &#xa0;L, Elvan &#xa0;A, et al. &#xa0;Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med &#xa0;2020;383:1305&#x2013;16. doi:10.1056/NEJMoa2019422</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2019422</ArticleId><ArticleId IdType="pubmed">32865375</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottschalk &#xa0;S, Kany &#xa0;S, K&#xf6;nig &#xa0;HH, Crijns &#xa0;HJ, Vardas &#xa0;P, Camm &#xa0;AJ, et al. &#xa0;Cost-effectiveness of early rhythm control vs. usual care in atrial fibrillation care: an analysis based on data from the EAST-AFNET 4 trial. Europace &#xa0;2023;25:euad051. doi:10.1093/europace/euad051</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euad051</ArticleId><ArticleId IdType="pmc">PMC10227663</ArticleId><ArticleId IdType="pubmed">36966734</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnabel &#xa0;RB, Marinelli &#xa0;EA, Arbelo &#xa0;E, Boriani &#xa0;G, Boveda &#xa0;S, Buckley &#xa0;CM, et al. &#xa0;Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference. Europace &#xa0;2023;25:6&#x2013;27. doi:10.1093/europace/euac062</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euac062</ArticleId><ArticleId IdType="pmc">PMC9907557</ArticleId><ArticleId IdType="pubmed">35894842</ArticleId></ArticleIdList></Reference><Reference><Citation>Metzner &#xa0;A, Suling &#xa0;A, Brandes &#xa0;A, Breithardt &#xa0;G, Camm &#xa0;AJ, Crijns &#xa0;HJGM, et al. &#xa0;Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST&#x2014;AFNET 4 trial. Europace &#xa0;2022;24:552&#x2013;64. doi:10.1093/europace/euab200</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euab200</ArticleId><ArticleId IdType="pmc">PMC8982435</ArticleId><ArticleId IdType="pubmed">34473249</ArticleId></ArticleIdList></Reference><Reference><Citation>Imberti &#xa0;JF, Mei &#xa0;DA, Vitolo &#xa0;M, Bonini &#xa0;N, Proietti &#xa0;M, Potpara &#xa0;T, et al. &#xa0;Comparing atrial fibrillation guidelines: focus on stroke prevention, bleeding risk assessment and oral anticoagulant recommendations. Eur J Intern Med &#xa0;2022;101:1&#x2013;7. doi:10.1016/j.ejim.2022.04.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2022.04.023</ArticleId><ArticleId IdType="pubmed">35525635</ArticleId></ArticleIdList></Reference><Reference><Citation>Lip &#xa0;GYH, Proietti &#xa0;M, Potpara &#xa0;T, Mansour &#xa0;M, Savelieva &#xa0;I, Tse &#xa0;HF, et al. &#xa0;Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal. Europace &#xa0;2023;25:euad226. doi:10.1093/europace/euad226</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euad226</ArticleId><ArticleId IdType="pmc">PMC10451006</ArticleId><ArticleId IdType="pubmed">37622590</ArticleId></ArticleIdList></Reference><Reference><Citation>Boriani &#xa0;G, Bonini &#xa0;N, Imberti &#xa0;JF, Vitolo &#xa0;M, Gerra &#xa0;L, Mantovani &#xa0;M, et al. &#xa0;Clinical decisions for appropriate management of patients with atrial fibrillation. Panminerva Med &#xa0;2024;Epub ahead of print. doi:10.23736/S0031-0808.24.05114-0</Citation><ArticleIdList><ArticleId IdType="doi">10.23736/S0031-0808.24.05114-0</ArticleId><ArticleId IdType="pubmed">38656767</ArticleId></ArticleIdList></Reference><Reference><Citation>Rillig &#xa0;A, Eckardt &#xa0;L, Borof &#xa0;K, Camm &#xa0;AJ, Crijns &#xa0;HJGM, Goette &#xa0;A, et al. &#xa0;Safety and efficacy of long-term sodium channel blocker therapy for early rhythm control: the EAST-AFNET 4 trial. Europace &#xa0;2024:euae121. doi:10.1093/europace/euae121</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euae121</ArticleId><ArticleId IdType="pmc">PMC11154137</ArticleId><ArticleId IdType="pubmed">38702961</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeppenfeld &#xa0;K, Tfelt-Hansen &#xa0;J, de Riva &#xa0;M, Winkel &#xa0;BG, Behr &#xa0;ER, Blom &#xa0;NA, et al. &#xa0;2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J &#xa0;2022;43:3997&#x2013;4126. doi:10.1093/eurheartj/ehac262</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehac262</ArticleId><ArticleId IdType="pubmed">36017572</ArticleId></ArticleIdList></Reference><Reference><Citation>Joglar &#xa0;JA, Chung &#xa0;MK, Armbruster &#xa0;AL, Benjamin &#xa0;EJ, Chyou &#xa0;JY, Cronin &#xa0;EM, et al. &#xa0;2023 ACC/AHA/ACCP/HRS Guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation &#xa0;2024;149:e1&#x2013;156. doi:10.1161/CIR.0000000000001193</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000001193</ArticleId><ArticleId IdType="pmc">PMC11095842</ArticleId><ArticleId IdType="pubmed">38033089</ArticleId></ArticleIdList></Reference><Reference><Citation>Savelieva &#xa0;I, Fumagalli &#xa0;S, Kenny &#xa0;RA, Anker &#xa0;S, Benetos &#xa0;A, Boriani &#xa0;G, et al. &#xa0;EHRA expert consensus document on the management of arrhythmias in frailty syndrome, endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace &#xa0;2023;25:1249&#x2013;76. doi:10.1093/europace/euac123</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euac123</ArticleId><ArticleId IdType="pmc">PMC10105859</ArticleId><ArticleId IdType="pubmed">37061780</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu &#xa0;VC, Wang &#xa0;CL, Huang &#xa0;YC, Tu &#xa0;HT, Huang &#xa0;YT, Huang &#xa0;CH, et al. &#xa0;Cardiovascular outcomes in patients with atrial fibrillation concomitantly treated with antiarrhythmic drugs and non-vitamin k antagonist oral anticoagulants. Europace &#xa0;2023;25:euad083. doi:10.1093/europace/euad083</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euad083</ArticleId><ArticleId IdType="pmc">PMC10227765</ArticleId><ArticleId IdType="pubmed">37000581</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashraf &#xa0;H, Ko &#xa0;NK, Ladia &#xa0;V, Agasthi &#xa0;P, Prendiville &#xa0;T, O'Herlihy &#xa0;F, et al. &#xa0;Use of flecainide in stable coronary artery disease: an analysis of its safety in both nonobstructive and obstructive coronary artery disease. Am J Cardiovasc Drugs &#xa0;2021;21:563&#x2013;72. doi:10.1007/s40256-021-00483-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40256-021-00483-9</ArticleId><ArticleId IdType="pubmed">34142347</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnham &#xa0;TS, May &#xa0;HT, Bair &#xa0;TL, Anderson &#xa0;JA, Crandall &#xa0;BG, Cutler &#xa0;MJ, et al. &#xa0;Long-term outcomes in patients treated with flecainide for atrial fibrillation with stable coronary artery disease. Am Heart J &#xa0;2022;243:127&#x2013;39. doi:10.1016/j.ahj.2021.08.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahj.2021.08.013</ArticleId><ArticleId IdType="pubmed">34537183</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiani &#xa0;S, Sayegh &#xa0;MN, Ibrahim &#xa0;R, Bhatia &#xa0;NK, Merchant &#xa0;FM, Shah &#xa0;AD, et al. &#xa0;The feasibility and safety of flecainide use among patients with varying degrees of coronary disease. JACC Clin Electrophysiol &#xa0;2023;9:1172&#x2013;80. doi:10.1016/j.jacep.2022.12.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacep.2022.12.021</ArticleId><ArticleId IdType="pubmed">36898953</ArticleId></ArticleIdList></Reference><Reference><Citation>Camm &#xa0;AJ, Blomstr&#xf6;m-Lundqvist &#xa0;C, Boriani &#xa0;G, Goette &#xa0;A, Kowey &#xa0;PR, Merino &#xa0;JL, et al. &#xa0;AIM-AF: a Physician Survey in the United States and Europe. J Am Heart Assoc &#xa0;2022;11:e023838. doi:10.1161/JAHA.121.023838</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.121.023838</ArticleId><ArticleId IdType="pmc">PMC9075271</ArticleId><ArticleId IdType="pubmed">35243874</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiffel &#xa0;JA, Blomstr&#xf6;m-Lundqvist &#xa0;C, Boriani &#xa0;G, Goette &#xa0;A, Kowey &#xa0;PR, Merino &#xa0;JL, et al. &#xa0;Real-world utilization of the pill-in-the-pocket method for terminating episodes of atrial fibrillation: data from the multinational Antiarrhythmic Interventions for Managing Atrial Fibrillation (AIM-AF) survey. Europace &#xa0;2023;25:euad162. doi:10.1093/europace/euad162</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euad162</ArticleId><ArticleId IdType="pmc">PMC10290490</ArticleId><ArticleId IdType="pubmed">37354453</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung &#xa0;SC, Lai &#xa0;A, Lip &#xa0;GYH, Lambiase &#xa0;PD, Providencia &#xa0;R. Impact of anti-arrhythmic drugs and catheter ablation on the survival of patients with atrial fibrillation: a population study based on 199 433 new-onset atrial fibrillation patients in the UK. Europace &#xa0;2023;25:351&#x2013;9. doi:10.1093/europace/euac155</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euac155</ArticleId><ArticleId IdType="pmc">PMC10103560</ArticleId><ArticleId IdType="pubmed">36106534</ArticleId></ArticleIdList></Reference><Reference><Citation>Boriani &#xa0;G, Imberti &#xa0;JF, Leyva &#xa0;F, Casado-Arroyo &#xa0;R, Chun &#xa0;J, Braunschweig &#xa0;F, et al. &#xa0;Length of hospital stay for elective electrophysiological procedures: a survey from the European Heart Rhythm Association. Europace &#xa0;2023;25:euad297. doi:10.1093/europace/euad297</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euad297</ArticleId><ArticleId IdType="pmc">PMC10563655</ArticleId><ArticleId IdType="pubmed">37789664</ArticleId></ArticleIdList></Reference><Reference><Citation>Remme &#xa0;CA, Heijman &#xa0;J, Gomez &#xa0;AM, Zaza &#xa0;A, Odening &#xa0;KE. 25 years of basic and translational science in EP Europace: novel insights into arrhythmia mechanisms and therapeutic strategies. Europace &#xa0;2023;25:euad210. doi:10.1093/europace/euad210</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euad210</ArticleId><ArticleId IdType="pmc">PMC10450791</ArticleId><ArticleId IdType="pubmed">37622575</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>